OraSure Technologies, Inc.  

(Public, NASDAQ:OSUR)   Watch this stock  
Find more results for OSUR
13.74
-0.35 (-2.48%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.64 - 14.07
52 week 8.21 - 23.01
Open 13.99
Vol / Avg. 1.20M/1.19M
Mkt cap 833.31M
P/E 26.45
Div/yield     -
EPS 0.52
Shares 60.65M
Beta 1.39
Inst. own 98%
Feb 8, 2018
Q4 2017 OraSure Technologies Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 9, 2017
OraSure Technologies Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Nov 8, 2017
OraSure Technologies Inc at Stephens Fall Investment Conference
Nov 1, 2017
Q3 2017 OraSure Technologies Inc Earnings Call - Webcast
Nov 1, 2017
Q3 2017 OraSure Technologies Inc Earnings Release
Sep 26, 2017
OraSure Technologies Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017
OraSure Technologies Inc at CL King & Associates Best Ideas Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 13.62% 15.38%
Operating margin 17.30% 15.81%
EBITD margin - 20.24%
Return on average assets 8.55% 9.93%
Return on average equity 9.65% 11.42%
Employees 325 -
CDP Score - -

Address

150 WEBSTER ST
BETHLEHEM, PA 18015
United States - Map
+1-503-6416115 (Phone)
+1-610-8821830 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

Officers and directors

Stephen S. Tang Ph.D. Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Douglas A. Michels President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald H. Spair Chief Financial Officer, Chief Operating Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony Zezzo II Executive Vice President - Marketing and Sales
Age: 63
Bio & Compensation  - Reuters
Mark L. Kuna Senior Vice President - Finance, Controller, Assistant Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Reed Ph.D. Senior Vice President - Research and Development, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Jack E. Jerrett Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mara Glickman Aspinall Director
Age: 54
Bio & Compensation  - Reuters
Michael Celano Independent Director
Age: 58
Bio & Compensation  - Reuters
Eamonn P. Hobbs Independent Director
Age: 58
Bio & Compensation  - Reuters